CD93-An emerging vascular target in cancer therapy

Area of Science:

• Biochemistry
• Molecular Biology
• Immunology

Background:

• CD93 is a transmembrane glycoprotein in the C-type lectin superfamily.
• Primarily expressed on endothelial cells, CD93 is a key regulator of angiogenesis.
• CD93 signaling pathways control endothelial cell migration and adhesion.

Purpose of the Study:

• To review and summarize literature on CD93's structure and signaling.
• To examine CD93's role in cancer prognosis and therapeutic targeting.
• To highlight CD93 as a promising target for cancer treatment.

Main Methods:

• Literature review and synthesis of existing research on CD93.
• Analysis of CD93's involvement in various pathologies, particularly cancer.
• Assessment of current therapeutic strategies targeting CD93.

Main Results:

• CD93 is upregulated in inflammatory conditions and cancers.
• CD93's interactions with ligands activate downstream signaling pathways.
• Evidence suggests CD93's contribution to cancer progression and prognosis.

Conclusions:

• CD93 is a significant therapeutic target for cancer treatment.
• Further translational efforts are needed to develop CD93-targeted therapies.
• Future research should focus on optimizing CD93-targeting strategies.